Editing 1996 in science (section)

==Medicine==
* March
** The [[Cochrane Library]] launched.<ref>{{cite web|title=About the Cochrane Library|url=http://www.thecochranelibrary.com/view/0/AboutTheCochraneLibrary.html#ABOUT|publisher=The [[Cochrane Library]]|accessdate=2011-01-25|archiveurl=https://web.archive.org/web/20110105124021/http://www.thecochranelibrary.com/view/0/AboutTheCochraneLibrary.html#ABOUT|archivedate=2011-01-05|url-status=dead}}</ref>
** The role of [[CCR5]] in [[HIV/AIDS]] infection begins to be published.<ref>{{cite journal|last1=Samson|first1=M.|last2=Labbe|first2=O.|display-authors=1|title=Molecular cloning and functional expression of a new human CC-chemokine receptor gene|journal=[[Biochemistry (journal)|Biochemistry]]|volume=35|issue=11|pages=3362–7|date=March 1996|pmid=8639485|doi=10.1021/bi952950g}}</ref>
* July 7–12 – [[XI International AIDS Conference, 1996]], [[Vancouver]], reports major advances in the [[management of HIV/AIDS]] including [[combination therapy]] (the "triple cocktail") using [[Protease inhibitor (pharmacology)|protease inhibitor]]s.<ref>{{cite journal|first=S. M.|last=Hammer|display-authors=etal|title=A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection|journal=[[The New England Journal of Medicine]]|volume=337|issue=11|pages=725–33|date=September 1997|pmid=9287227|doi=10.1056/NEJM199709113371101|s2cid=24043435 |doi-access=free}}</ref> Within a week after the conference, over 75,000 patients who have been using antibiotics and chemotherapy as treatment against [[opportunistic infections]] begin an effective antiviral regimen which greatly increases their immune system strength and therefore their health.<ref>{{cite book|last=Engel|first=Jonathan|title=The Epidemic|year=2006|publisher=Smithsonian Books/Collins|location=New York|isbn=978-0-06-114488-2|page=246|url=https://archive.org/details/epidemicaglobalh00enge/page/246}}</ref>
* New variant [[Creutzfeldt–Jakob disease]] first identified in humans, in the United Kingdom.<ref>{{cite journal |doi=10.1016/S0140-6736(96)91412-9 |pmid=8598754 |title=A new variant of Creutzfeldt-Jakob disease in the UK |journal=The Lancet |volume=347 |issue=9006 |pages=921–925 |year=1996 |last1=Will |first1=R. G.|last2=Ironside |first2=J. W.|last3=Zeidler |first3=M. |last4=Estibeiro |first4=K. |last5=Cousens |first5=S. N.|last6=Smith |first6=P. G.|last7=Alperovitch |first7=A. |last8=Poser |first8=S. |last9=Pocchiari |first9=M. |last10=Hofman |first10=A. |s2cid=14230097 }}</ref>
* [[Montreal Cognitive Assessment]] is created by [[Ziad Nasreddine]] in [[Montreal]], [[Quebec]].<ref>{{cite journal|last=Nasreddine|first=Z. S.|display-authors=etal|title=The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment|journal=Journal of the American Geriatrics Society|volume=53|issue=4|pages=695–9|year=2005|pmid=15817019|doi=10.1111/j.1532-5415.2005.53221.x|s2cid=9014589}}</ref>
* [[Donepezil]] (Aricept), a palliative treatment for moderate [[Alzheimer's disease]], is [[Approved drug|approved]] in the United States.<ref>{{cite book |doi=10.1016/B0-08-043076-7/03738-4 |chapter=Alzheimer's Disease: Antidementive Drugs |title=International Encyclopedia of the Social & Behavioral Sciences |pages=418–423 |year=2001 |last1=Hofmann |first1=M. |last2=Hock |first2=C. |isbn=9780080430768 }}</ref><ref>{{cite book |doi=10.1016/B978-012351830-9/50034-2 |chapter=Cholinergic Treatments of Alzheimer's Disease |title=Functional Neurobiology of Aging |pages=475–486 |year=2001 |last1=Tsopelas |first1=Nicholas D. |last2=Marin |first2=Deborah B. |isbn=9780123518309 }}</ref><ref>{{cite book |doi=10.1016/B0-08-045044-X/00168-1 |chapter=Neurodegeneration |title=Comprehensive Medicinal Chemistry II |pages=193–228 |year=2007 |last1=Bozyczko-Coyne |first1=D. |last2=Williams |first2=M. |isbn=9780080450445 }}</ref>
* [[Sildenafil]] (Viagra), a treatment for [[erectile dysfunction]], is [[patent]]ed by [[Pfizer]].<ref>{{cite journal |pmid=8858389 |title=Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction |journal=International Journal of Impotence Research |volume=8 |issue=2 |pages=47–52 |year=1996 |last1=Boolell |first1=M. |last2=Allen |first2=M. J. |last3=Ballard |first3=S. A. |last4=Gepi-Attee |first4=S. |last5=Muirhead |first5=G. J. |last6=Naylor |first6=A. M. |last7=Osterloh |first7=I. H. |last8=Gingell |first8=C. }}</ref>